NCT01280487已完成1 期
A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 3
- 主要终点
- Maximum tolerated dose
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of daily oral doses of ZSTK474, an oral phosphatidylinositol 3-kinase (PI3K) inhibitor, in subjects with advanced solid malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or females ≥18 years of age;
- •Histologically-confirmed advanced (metastatic or unresectable) solid tumor - for which available therapy is not effective;
- •ECOG performance status score of ≤2 and an expected survival of >8 weeks;
- •Recovered from the toxicities of prior chemotherapy, radiotherapy, and other cancer therapies; all toxicities must be determined to be below Grade 2 (assessed using the NCI CTCAE v4.0).
- •Adequate blood counts with a hemoglobin (Hgb) of ≥9.0 mg/dL, absolute neutrophil count (ANC) >1,500/mm3, and platelets ≥100,000/mm3 (all without transfusion support);
- •Subjects who are willing and able to provide written informed consent.
- •In the expanded cohort at the MTD only: Subjects must be willing to undergo mandatory biopsies of tumor tissue twice during the first cycle (before and during dosing) and must have tumor tissue in a location accessible to incisional biopsy of a superficial lesion or percutaneous core needle biopsy on an outpatient basis without undue risk to the subject.
排除标准
- •Women who are pregnant or breastfeeding;
- •Men or women of reproductive potential who are not willing to use acceptable means of contraception while on study drug and for an additional 90 days after the last dose of study drug;
- •Body Mass Index (BMI) is ≥30 kg/m2;
- •Have primary central nervous system (CNS) tumors or untreated/uncontrolled CNS metastases; Note: Subjects with stable/controlled CNS metastases may be enrolled (i.e., if CNS lesions have been stable in size for at least one month and the subject is off steroid and anti-convulsants).
- •Have received any investigational interventional agents within the 4 weeks prior to the start of dosing with ZSTK474;
- •Are receiving concurrent anti-tumor chemotherapy, radiotherapy, or immunotherapy - or have received any of these non-investigational agents within the previous 4 weeks or 5-half-lives (whichever is longer) prior to the start of dosing with ZSTK474;
- •Are not able or willing to comply with the study procedures, including the study visit schedule;
- •Have previously been treated with a phosphatidylinositol 3 kinase (PI3K) inhibitor;
- •Have serious or significant intercurrent illnesses or underlying diseases, such as:
- •Gastrointestinal disorder
- •Hepatic: AST or ALT >2.5 x ULN (or >5.0 x ULN with liver metastases) or serum bilirubin >1.5 x ULN;
- •Renal (acute or chronic renal disease or eGFR <55 mL/min)
- •Cardiovascular:
- •Uncontrolled hypertension or blood pressure >140/90 mmHg;
- •Symptomatic congestive heart failure;
- •Myocardial infarction within the past 6 months;
- •Unstable angina pectoris;
- •Cardiac arrhythmia;
- •Congenital long QT syndrome;
- •QTc >450 msec for men or >470 msec for women.
- •Known diagnosis of HIV infection;
- •Other ongoing or active infections;
- •Psychiatric illness, substance abuse or social situation that would preclude study compliance.
- •Other serious concurrent illness that would preclude assessment of drug effect;
- •PT/PTT)/APTT/INR >ULN for subjects not on anti-coagulants; INR > 1.5 x ULN for subjects on low dose warfarin.
- •Current treatment with the following drugs:
- •any anti-seizure medications;
- •therapeutic anti-coagulant doses of warfarin.
研究组 & 干预措施
Oral ZSTK474
Experimental
Daily oral dosing for 21 days per cycle
干预措施: ZSTK474 (Drug)
结局指标
主要结局
Maximum tolerated dose
时间窗: 21 days
次要结局
- Pharmacokinetics(21 days)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesRelapsed or Refractory Haematological Malignancies IncludingAcute Lymphocytic LeukemiaHigh Risk Myelodysplastic SyndromeAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaRichter's SyndromeB-cell Non-Hodgkin LymphomaT-cell Non-Hodgkin LymphomaSmall Lymphocytic LymphomaMultiple MyelomaChronic Myelomonocytic LeukemiaNCT03263637AstraZeneca44
Unknown
1 期
A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML)Acute Myeloid LeukemiaNCT04827069Sunshine Lake Pharma Co., Ltd.80
招募中
1 期
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced MalignanciesAdvanced Solid TumorsNCT05164458Innovent Biologics (Suzhou) Co. Ltd.320
终止
1 期
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene AlterationsSolid Tumor, AdultUrothelial CarcinomaIntrahepatic CholangiocarcinomaNCT05242822Kinnate Biopharma54
已完成
1 期
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsSolid TumorsNCT04774952Revolution Medicines, Inc.58